Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Shots:
- The US FDA has granted orphan drug designation to the company’s certepetide for treating cholangiocarcinoma
- Certepetide is being assessed under the P-IIa clinical evaluation for its preliminary efficacy, safety and tolerability in addition to SoC vs PBO + SoC alone as a 1L and 2L treatment of cholangiocarcinoma
- Certepetide activates the C-end rule transport mechanism for effective tumor-specific delivery of co-administered anti-cancer drugs. It also reduces immunosuppression and inhibit metastasis by modifying the tumor microenvironment
Ref: Lisata Therapeutics | Image: Lisata Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
